ASP Isotopes Tech-Economic Report: QE/ASP vs. Legacy Enrichment
2/14/26
SEQH Capital Research
Tech-Economics: ASP/QE vs. Legacy Enrichment
A Financial Cost-Curve Study of ASPI’s Enrichment Technologies
Tear Sheet – February 14, 2026
Why This Matters
Every bull thesis on ASP Isotopes (ASPI) claims its technology is “cheaper” than incumbents. This report shows the math, building side-by-side cost stacks across six enrichment methods, mapping margin structures per isotope, and modeling break-even utilization at scale.
Two Technologies, Two Markets
ASP (Aerodynamic Separation Process): Dominates light stable isotopes (below ~100 AMU) where it competes against Russian calutrons. Pharma-grade margins (75–85%). Not competitive for bulk uranium enrichment, and doesn’t need to be.
QE (Quantum Enrichment): Laser-based enrichment targeting heavy metals and HALEU. Demonstrated enrichment factor of up to 678. Single-stage natural-to-HALEU potential. ~40 kWh/SWU energy consumption, matching centrifuges. Asymmetric option on disrupting the multi-billion-dollar nuclear fuel chain.
Cost-Curve Positioning
Gas centrifuges (incumbent): 1–5 billion dollars per facility, 5–10+ years to build, 40–50 kWh/SWU, separation factor ~1.15, utility-grade margins (30–40%).
ASP (ASPI): 2.5–30 million dollars per plant, 9–12 months to build, 300–500 kWh/SWU (higher energy but offset by dramatically lower capex and Iceland electricity at under 0.05 dollars per kWh), separation factor 1.1–1.19, pharma-grade margins (75–85%).
QE (ASPI): 2.5–100 million dollars per plant, 9–18 months to build, ~40 kWh/SWU (matching centrifuges), separation factor 50–678, margin profile ranges from pharma to industrial depending on isotope.
Near-Term Revenue: Specialty Isotope Margins
Si-28: ~75% gross margin at 550 dollars per gram. Plant cost ~25M, break-even ~1 year.
Yb-176: ~85% gross margin. QE plant cost 2.5M, break-even in under 2 months at full utilization.
C-14: ~85% gross margin. Break-even Year 1–2.
Ni-64: Market price 40M dollars per kg, margins estimated above 80%.
The HALEU Wild Card (QE)
If QE achieves all-in enrichment cost of 50–100 dollars per SWU, modeled HALEU cost drops to ~15,500 dollars per kgU, a 35% reduction vs. the NIA baseline of 23,725 dollars per kgU and below the ~20,000 dollar current market price.
At 30–50 dollars per SWU, total HALEU cost drops to 11,000–13,000 dollars per kgU, transformational for every HALEU-fueled SMR under development.
Hypothetical HALEU QE plant: under 100M dollars capex, 20 MTU/year capacity, 360–400M dollars annual revenue at full utilization, break-even in under 1 year.
Key Risks
QE has not been demonstrated on uranium at scale since the 1980s; engineering gap from Yb to U-235 at 20 MTU/year is nontrivial.
HALEU regulatory licensing is multi-year and unpredictable across jurisdictions.
ASP energy costs (300–500 kWh/SWU) limit it to non-uranium isotopes; Iceland move de-risks this.
Calutron replacement moat could erode if CNNC or Western competitors scale alternatives.
Dilution risk: ~100M+ in equity raised plus 98M in convertible notes against 7.2M trailing 9-month revenue and 96.5M net loss.
SEQH View
ASPI is a two-technology portfolio with radically different competitive positioning. ASP dominates a niche, high-margin, supply-constrained stable isotope market today. QE represents an asymmetric option on disrupting the multi-billion-dollar HALEU enrichment chain. The cost-curve data validates genuine economic advantages in both domains, but HALEU remains pre-revenue and pre-regulatory, investors should weight the near-term isotope cash flows and treat the HALEU opportunity as high-conviction upside optionality.
Want the Full Cost-Curve Deep Dive?
[READ THE COMPLETE TECH-ECONOMICS REPORT]
The full report includes analysis you won’t find anywhere else:
Complete side-by-side cost stacks across all six enrichment methods (gaseous diffusion, centrifuge, AVLIS, SILEX, ASP, QE)
Detailed separation factor and energy consumption benchmarking with source data from Klydon technical papers
Bottom-up unit economics for every ASPI isotope plant (Si-28, C-14, Yb-176, Ni-64, HALEU)
Full HALEU cost-curve modeling under Q, the analysis no sell-side firm has published
Break-even utilization analysis for each facility with revenue and payback projections
Capital intensity comparison vs. Centrus, Orano, Urenco, and SILEX/GLE
Iceland energy arbitrage quantification and its impact on ASP economics at scale
Dilution-adjusted return framework incorporating convertible note overhang
Isotope-by-isotope competitive moat assessment vs. Rosatom, CNNC, and Western alternatives
This is the only publicly available report that translates ASPI’s physics into investable financial frameworks. If you’re sizing a position in ASPI, you need this math.
Available exclusively to SEQH Capital Research paid subscribers. Upgrade to access →
